<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study was conducted with an aim to explore the possible role of <z:chebi fb="0" ids="28819">naringin</z:chebi> against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion induced-neurobehavioral alterations, oxidative damage, cellular and histopathological alterations in cortex, striatum, hippocampus areas of brain </plain></SENT>
<SENT sid="1" pm="."><plain>Male Wistar rats (200-220 g) were subjected to bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 30 min followed by reperfusion for 24 h to induce reperfusion (I/R) cerebral injury </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="28819">Naringin</z:chebi> (50, 100 mg/kg, i.p.) was administered for 7 days continuously before animals were subjected to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion injury </plain></SENT>
<SENT sid="3" pm="."><plain>Various behavioral tests [locomotor activity, neurological score (inclined beam test), transfer latency, resistance to lateral push] and biochemical parameters (<z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, <z:chebi fb="95" ids="16301">nitrite</z:chebi> level, reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi>, <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase and catalase activity), <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme dysfunctions (Complex I, II, III and IV) in cortex, striatum, hippocampus of brain and histopathological alterations were assessed subsequently </plain></SENT>
<SENT sid="4" pm="."><plain>Seven days <z:chebi fb="0" ids="28819">naringin</z:chebi> (50 and 100 mg/kg) treatment significantly improved neurobehavioral alterations (improved locomotor activity, inclined beam walking and reduced resistance to lateral push, transfer latency) as compared to control <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="28819">Naringin</z:chebi> (50 mg/kg and 100 mg/kg) treatment significantly attenuated oxidative damage as indicated by reduced <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, <z:chebi fb="95" ids="16301">nitrite</z:chebi> concentration, restored reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> and catalase activity and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme activities in cortex, striatum, cerebellum as compared to control (<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion) animals </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:chebi fb="0" ids="28819">naringin</z:chebi> treatment significantly reversed histopathological alterations in cortex, striatum, hippocampus areas as compared to control (<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion) </plain></SENT>
<SENT sid="7" pm="."><plain>Present study suggests the protective effect of <z:chebi fb="0" ids="28819">naringin</z:chebi> and its therapeutic potential against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion induced and related behavioral alterations in rats </plain></SENT>
</text></document>